Is Compounded Tirzepatide Still Available? Yes, Under Specific Conditions

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Compounded tirzepatide remains available through licensed 503A compounding pharmacies for patients with documented clinical justification
• The October 2, 2024 FDA shortage resolution ended the broader shortage-based pathway but did not affect the 503A patient-specific pathway
• The 503A pathway is preserved by federal statute (Section 503A, 21 U.S.C. § 353a) and operates under state pharmacy board oversight
• Availability now depends on prescriber documentation of a specific clinical reason that brand Mounjaro or Zepbound cannot meet
• For patients without specific clinical justification, brand alternatives including LillyDirect self-pay vials at $349-$699/month may be more accessible than during the shortage

Direct answer

Yes, compounded tirzepatide is still available in 2026 through licensed 503A pharmacies for patients with documented individualized clinical reasons. The pathway is narrower than during the 2022-2024 shortage period but is preserved by federal statute and continues to operate. Patients who do not have specific clinical justification are typically directed toward brand Zepbound or Mounjaro, including through manufacturer self-pay programs.

Table of contents

1. The availability picture in 2026, summarized
2. The two compounding tracks and what survived October 2024
3. What "documented clinical reason" looks like in practice
4. Verifying that your source is legitimate
5. Pricing changes since the shortage ended
6. The transition from compounded to brand (and back)
7. What happens if availability shifts again
8. The contrary view: arguments against continued compounding
9. Decision framework
10. FAQ
11. Sources

The availability picture in 2026, summarized

The compounded tirzepatide market looks different in 2026 than it did in 2023. The shift in three dimensions:

Dimension	2023 (shortage era)	2026 (post-shortage)
Primary compounding source	503B outsourcing facilities (high volume)	503A pharmacies (patient-specific)
Required justification	Shortage status sufficient	Individualized clinical reason required
Typical monthly cost	$150-$400	$250-$500
Brand alternative cost	$1,000-$1,300 (mostly unavailable due to shortage)	$349-$699 via LillyDirect self-pay; widely available
Number of platforms offering it	50+ telehealth platforms	Smaller number, more rigorous intake
Regulatory clarity	FDA shortage list provided clear authority	503A patient-specific pathway, narrower but settled

Availability did not disappear. The market consolidated around the 503A patient-specific pathway, with more rigorous intake, narrower clinical criteria, and modest price increases reflecting the shift from batch to individualized compounding.

The two compounding tracks and what survived October 2024

Federal pharmacy law splits compounders into 503A and 503B categories. The October 2, 2024 shortage resolution affected each differently:

503B Outsourcing Facilities:

• Regulated by the FDA
• Produce batches without patient-specific prescriptions
• Drove most of the high-volume compounded tirzepatide market during the shortage
• Lost authority to compound tirzepatide when shortage status was resolved
• The Outsourcing Facilities Association legal challenge to the FDA's decision was denied in March 2025, foreclosing this pathway

503A Compounding Pharmacies:

• Regulated primarily by state boards of pharmacy
• Compound patient-specific prescriptions for individual patients
• Retain authority under federal statute (predates the shortage by 25 years)
• Continue to compound tirzepatide when prescribers document clinical justification
• This is the pathway that survived October 2024 and remains active

The 503A pathway is not a loophole. It is the original framework Congress established in the Food and Drug Administration Modernization Act of 1997 for legitimate patient-specific compounding. The framework predates tirzepatide and applies to many medications beyond GLP-1s.

What "documented clinical reason" looks like in practice

The clinical reason that justifies 503A compounding must be documented in the patient's medical record and on the prescription. Common reasons that satisfy the requirement:

• Inactive ingredient sensitivity. The patient has a documented adverse reaction to a specific excipient or preservative in brand Mounjaro or Zepbound. The compounded preparation omits the triggering ingredient.
• Intermediate dose strength. The patient cannot tolerate the standard titration steps from 2.5 mg to 5 mg, requiring an intermediate dose like 3.75 mg that is not commercially available. The compounded preparation provides the specific dose.
• Concentration adjustment. The patient has injection-site reactions with the standard concentration of commercial product. The compounded preparation uses a different concentration to reduce injection volume.
• Preservative-free formulation. The patient has documented sensitivity to common preservatives like benzyl alcohol. The compounded preparation is preservative-free.
• Drug interaction or allergy profile. The patient has a specific medical situation that requires an unusual formulation profile.

What does not satisfy the requirement: cost preference, convenience, or simply preferring the compounded version. These are real concerns but they are not the clinical justification 503A requires.

Verifying that your source is legitimate

Verification is straightforward if you know what to look for:

1. Named pharmacy. The telehealth platform names its 503A pharmacy partner. The pharmacy has a physical address, state license, and verifiable presence in pharmacy board records.
2. State license verification. Each state's board of pharmacy publishes a license verification tool. Confirm the pharmacy holds active 503A licensure.
3. Inspection history. State pharmacy boards inspect 503A operations on a defined schedule. Inspection reports are often publicly available or available on request. Recent reports without significant deficiencies indicate a well-run operation.
4. USP 797 compliance. Sterile compounding under USP 797 is required for injectable preparations like tirzepatide. The pharmacy should be able to describe its USP 797 program.
5. API sourcing. The active pharmaceutical ingredient should come from an FDA-registered API supplier. The pharmacy can document its supply chain.
6. Third-party testing. Best-practice operations test finished product for sterility, endotoxin, and potency through third-party labs at defined intervals.

Pricing changes since the shortage ended

Compounded tirzepatide prices rose modestly after October 2024. The factors:

• 503A patient-specific compounding has higher per-unit costs than 503B batch production. The shift to 503A as the primary pathway increased the cost floor.
• API sourcing got more expensive as the bulk import allowances tied to shortage status ended.
• Smaller pharmacy network and higher overhead per prescription affected pricing.

Typical 2026 compounded tirzepatide pricing through legitimate 503A channels: $250-$500 per month depending on dose and pharmacy. Some operations charge more for higher doses; some include onboarding or consultation fees that affect total monthly cost.

For comparison, the brand alternative through LillyDirect self-pay: $349 (2.5 mg vial), $499 (5 mg vial), $599 (7.5 mg vial), $699 (10 mg vial). For many patients, the brand-vs-compounded cost gap is now smaller than the headline numbers suggest.

The transition from compounded to brand (and back)

Many patients have transitioned between compounded and brand tirzepatide as the regulatory and pricing landscape shifted. Key considerations:

Compounded to brand transition: Generally straightforward. The active ingredient is the same molecule. Dosing translates directly between compounded and brand at the same mg dose. Some patients notice differences in injection experience or side effect profile due to formulation differences, but the clinical effect is similar.

Brand to compounded transition: Possible if a documented clinical reason emerges. A patient who develops a sensitivity to a specific brand inactive ingredient, for example, can transition to a compounded preparation that omits the triggering ingredient. The transition requires prescriber documentation of the clinical reason.

Dose continuity: Both directions typically maintain dose continuity. A patient on 7.5 mg compounded weekly transitions to 7.5 mg brand weekly without titration restart.

What happens if availability shifts again

Future scenarios worth tracking:

• New shortage declaration: If supply becomes constrained again (manufacturing disruption, demand surge, regulatory action), the FDA could place tirzepatide back on the shortage list. This would re-open broader compounding authority.
• Legislative changes: Congress could modify the 503A framework. No such legislation is pending. Modifying 503A would affect many medications beyond GLP-1s.
• FDA enforcement actions: The FDA can take action against specific compounding operations for quality, safety, or compliance issues. This affects individual pharmacies, not the pathway itself.
• Manufacturer pricing changes: Eli Lilly could expand or contract LillyDirect self-pay availability, affecting the comparative economics of compounded vs brand.

For patients currently on compounded tirzepatide, the most useful approach is to maintain a working relationship with a prescriber who can adjust the plan if availability shifts.

The contrary view: arguments against continued compounding

A reasonable case against continued 503A tirzepatide compounding:

The 503A pathway was designed for situations where commercial alternatives genuinely cannot serve patient needs. Most current tirzepatide compounding involves variations (different doses, different concentrations) that produce small clinical differences. Critics argue this stretches the original 503A intent beyond its design.

Tirzepatide is a peptide that requires careful manufacturing controls. Critics argue that even the best 503A pharmacies have less rigorous manufacturing standards than cGMP, and that consistent quality is harder to achieve at the 503A scale.

With LillyDirect self-pay at $349-$699/month, the cost-driven case for compounded has weakened. Critics argue the practical justification for compounded has diminished even where the legal pathway remains.

The counter-position: 503A is settled federal law reflecting Congress's judgment about clinical autonomy. Even modest formulation differences can be clinically meaningful for individual patients. The pricing gap, while narrower, remains real for many patients.

Both views have merit. The legal framework reflects the counter-position; clinical practice incorporates both perspectives.

Decision framework

If you are currently on compounded tirzepatide: Confirm with your prescriber that the chart documents an individualized clinical reason. If yes, continued access is straightforward. If not, develop the documentation or consider transition to brand.

If you want to start compounded tirzepatide: Be prepared to discuss specific clinical reasons with your prescriber. If you do not have a documented reason, brand is likely the more appropriate path.

If you are evaluating cost: Compare your specific compounded pricing to LillyDirect vial pricing at your dose. The gap may be smaller than expected.

If you are uncertain about a source: Verify pharmacy licensure through state pharmacy boards. If a source cannot be verified, avoid it.

FAQ

Is compounded tirzepatide still available in 2026?
Yes, through licensed 503A pharmacies with documented clinical justification.

Which pharmacies still compound it?
Many state-licensed 503A pharmacies; telehealth platforms typically partner with vetted networks.

What changed after October 2024?
503B production ended; 503A patient-specific continues.

Can I switch from compounded back to brand?
Yes, dose continuity is typically maintained.

How do I know my compounded tirzepatide is real?
Verify pharmacy licensure, USP 797 compliance, named source, and third-party testing.

What clinical reasons keep me eligible?
Allergen sensitivity, dose individualization, concentration adjustment, preservative-free needs.

Is FormBlends still providing it?
Yes, through 503A pharmacy partners with documented clinical justification.

Is there a quality difference between compounded and brand?
Different regulatory frameworks, same active ingredient, different manufacturing scale and trial backing.

Why does compounded cost more now than 2023?
Patient-specific 503A compounding has higher per-unit costs than batch production.

Will availability change again?
Possible; track new shortage declarations or regulatory changes.

Sources

1. FDA Drug Shortage List update, October 2, 2024
2. Federal Food, Drug, and Cosmetic Act Section 503A, 21 U.S.C. § 353a
3. Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115)
4. USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations
5. Outsourcing Facilities Association v. FDA ruling, March 5, 2025
6. Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022
7. Eli Lilly LillyDirect platform information
8. National Association of Boards of Pharmacy resources
9. FDA Guidance on compounding under Section 503A
10. Zepbound and Mounjaro FDA prescribing information
11. State pharmacy board licensure databases (varies by state)
12. FDA enforcement actions against non-licensed sources, 2024-2025

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed clinicians and 503A compounding pharmacies. We are not a pharmacy or a medical practice; clinical decisions and dispensing rest with licensed professionals.

Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacy partners for individual patients based on prescriber-documented clinical reasons. Not FDA-approved. Not regulatorily equivalent to Mounjaro or Zepbound. SURMOUNT trial data applies to brand product.

Results Disclaimer. Individual outcomes vary. SURMOUNT-1 reported a 22.5% mean weight loss at the 15 mg dose over 72 weeks. Your result depends on dose, adherence, baseline weight, and individual response.

Trademark Notice. Mounjaro, Zepbound, LillyDirect, and SURMOUNT are trademarks or service marks of Eli Lilly and Company. FormBlends is independent.